[Treatment of acute non-lymphocytic leukemia with concurrent administration of N4-behenoyl-beta-D-arabinofuranosylcytosine, aclacinomycin A, 6-mercaptopurine and prednisolone; a pilot study (author's transl)].
D015250:Aclarubicin; D000328:Adult; D003561:Cytarabine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007938:Leukemia / Q000188:drug therapy*; D007948:Leukemia, Monocytic, Acute / Q000188:drug therapy; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy; D008297:Male; D015122:Mercaptopurine / Q000008:administration & dosage*; D008875:Middle Aged; D009279:Naphthacenes / Q000008:administration & dosage; D011239:Prednisolone / Q000008:administration & dosage*
D009279:Naphthacenes; D003561:Cytarabine; D015250:Aclarubicin; D011239:Prednisolone; C015019:enocitabine; D015122:Mercaptopurine